Skip to content

AbbVie

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile10 entries

  1. 2024

    Trade-secret lawsuit against BeiGene

    AbbVie sued BeiGene, alleging that a former AbbVie scientist took confidential information that was used in developing a competing blood-cancer treatment. The allegations were disputed and remained litigation claims rather than established findings.

  2. 2023

    AbbVie files patent lawsuit against BeiGene over Brukinsa

    Lawsuit filed

    AbbVie’s Pharmacyclics unit filed a lawsuit against BeiGene in federal court in Delaware, alleging that BeiGene’s Brukinsa infringes a patent on AbbVie’s Imbruvica. AbbVie sought a declaratory judgment of infringement and damages; BeiGene said it would vigorously defend against the allegations.

    Company response

    • Denial — BeiGene

      BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.

    Source excerpt

    • Through its complaint, filed the same day in federal court in Delaware, US, AbbVie is seeking a declaratory judgment of infringement, as well as damages.
    • AbbVie’s Pharmacyclics unit has filed a lawsuit against BeiGene, alleging that the biotech’s Brukinsa (zanubrutinib) infringes a patent on its own blood cancer drug Imbruvica (ibrutinib).
    • BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.
  3. 2022

    Opioid-marketing settlement involving Allergan

    AbbVie agreed to pay up to $2.37 billion to resolve U.S. litigation involving alleged opioid marketing by its Allergan unit. AbbVie denied wrongdoing.

  4. 2021

    Senate investigation into tax practices

    The United States Senate Finance Committee examined whether AbbVie used provisions of the 2017 tax law and offshore intellectual-property structures to reduce its U.S. tax liability.

  5. 2021

    BTL and AbbVie settle patent dispute

    Settlement

    BTL announced that it had resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the settlement, AbbVie will pay BTL an undisclosed amount, and pending litigation between the parties will be dismissed.

    Source excerpt

    • Under the terms of the settlement agreement, ABBVIE will pay BTL an undisclosed payment.
    • BTL Industries—a leading manufacturer of innovative aesthetic products—announced today that the company has resolved its patent infringement claims against ABBVIE related to BTL's muscle stimulation technology.
  6. 2021

    AbbVie files second suit against Alvotech

    Lawsuit filed

    AbbVie brought a second action against Alvotech hf. in the Northern District of Illinois, alleging patent infringement in connection with Alvotech’s proposed HUMIRA biosimilar.

    Source excerpt

    • On May 28, AbbVie brought a second action in the Northern District of Illinois for patent infringement against Alvotech hf. under the BPCIA in connection with Alvotech’s proposed biosimilar version of HUMIRA® (adalimumab).
  7. 2021

    Alvotech files suit against AbbVie over Humira patents

    Lawsuit filed

    Alvotech USA and Alvotech hf filed a declaratory-judgment complaint against AbbVie in the Eastern District of Virginia, alleging that patents in AbbVie’s Humira portfolio were invalid or unenforceable and seeking declaratory judgments of non-infringement and invalidity.

    Source excerpt

    • For each patent, the complaint asserts a claim for a declaratory judgment of non-infringement and invalidity.
    • On May 11, 2021, Alvotech USA and Alvotech hf (jointly, Alvotech) filed a complaint seeking declaratory judgement against AbbVie Inc. and AbbVie Biotechnology Ltd (jointly, AbbVie) in the Eastern District of Virginia.
  8. 2020

    Humira nurse-ambassador allegations

    AbbVie agreed to pay $24 million to resolve allegations concerning kickbacks connected with promotion of Humira through nurse-ambassador programs.

  9. 2020

    AbbVie settles California allegations over HUMIRA marketing

    Settlement

    AbbVie reached a settlement with California over allegations that it violated the state’s Insurance Frauds Prevention Act. The agreement requires changes to its HUMIRA marketing practices and a $24 million payment; AbbVie continued to deny wrongdoing.

    Company response

    • Denial — AbbVie

      The company also agreed to pay $24 million as part of the settlement despite continuing to deny any wrongdoing.

    Source excerpt

    • The settlement, reached Thursday, includes AbbVie’s agreement to alter its marketing practices for the drug HUMIRA, which is used primarily to treat inflammatory conditions like psoriasis, arthritis and Crohn’s Disease.
    • The pharmaceutical company AbbVie, Inc. has reached a settlement agreement with California over allegations that it violated the state’s Insurance Frauds Prevention Act.
    • The company also agreed to pay $24 million as part of the settlement despite continuing to deny any wrongdoing.
  10. 2018

    TriCor marketing settlement

    AbbVie agreed to pay $25 million to resolve allegations that unlawful kickback arrangements were used to promote TriCor. The resolution did not establish a criminal conviction by itself, and the company’s legal position should be distinguished from the allegations.